On 27 July 2020, orphan designation EU/3/20/2307 was granted by the European Commission to Mundipharma Corporation (Ireland) Limited, Ireland, for tinostamustine (also known as EDO-S101) for the treatment of T-cell prolymphocytic leukaemia.
|Disease / condition||
Treatment of T-cell prolymphocytic leukaemia
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
Mundipharma Corporation (Ireland) Limited
18 Arkle Road
Sandyford Industrial Estate
Tel. +353 1 2063800
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.